600056 中国医药
交易中 08-28 09:37:02
资讯
新帖
简况
中国医药（600056）2026年中报简析：净利润同比下降15.26%
证券之星 · 08-27 06:02
中国医药（600056）2026年中报简析：净利润同比下降15.26%
股市必读：中国医药中报 - 第二季度单季净利润同比下降44.88%
证券之星 · 08-27 02:20
股市必读：中国医药中报 - 第二季度单季净利润同比下降44.88%
图解中国医药中报：第二季度单季净利润同比下降44.88%
证券之星 · 08-26 01:40
图解中国医药中报：第二季度单季净利润同比下降44.88%
股市必读：中国医药（600056）8月18日董秘有最新回复
证券之星 · 08-19
股市必读：中国医药（600056）8月18日董秘有最新回复
中国医药：构建“小通智慧云药房”
证券之星 · 08-18
中国医药：构建“小通智慧云药房”
股市必读：中国医药（600056）8月17日董秘有最新回复
证券之星 · 08-18
股市必读：中国医药（600056）8月17日董秘有最新回复
每周股票复盘：中国医药（600056）子公司获氨甲环酸片上市许可
证券之星 · 08-16
每周股票复盘：中国医药（600056）子公司获氨甲环酸片上市许可
股市必读：中国医药新发布《关于子公司获得药品补充申请批准通知书的公告》
证券之星 · 08-12
股市必读：中国医药新发布《关于子公司获得药品补充申请批准通知书的公告》
中国医药（600056）披露子公司获得药品补充申请批准通知书，8月10日股价上涨0.74%
证券之星 · 08-10
中国医药（600056）披露子公司获得药品补充申请批准通知书，8月10日股价上涨0.74%
股市必读：中国医药新发布《关于子公司参加第十二批全国药品集中采购拟中选的公告》
证券之星 · 08-05
股市必读：中国医药新发布《关于子公司参加第十二批全国药品集中采购拟中选的公告》
股市必读：中国医药新发布《关于子公司参加第十二批全国药品集中采购拟中选的公告》
证券之星 · 08-04
股市必读：中国医药新发布《关于子公司参加第十二批全国药品集中采购拟中选的公告》
中国医药(600056.SH)：盐酸倍他司汀片等药品拟中选全国药品集中采购
智通财经 · 08-03
中国医药(600056.SH)：盐酸倍他司汀片等药品拟中选全国药品集中采购
每周股票复盘：中国医药（600056）拟出租美康大厦获年租金1047.25万
证券之星 · 08-02
每周股票复盘：中国医药（600056）拟出租美康大厦获年租金1047.25万
中国医药（600056）披露向关联方出租美康大厦事项，7月28日股价下跌0.43%
证券之星 · 07-28
中国医药（600056）披露向关联方出租美康大厦事项，7月28日股价下跌0.43%
每周股票复盘：中国医药（600056）子公司获布美他尼注射液批件
证券之星 · 07-26
每周股票复盘：中国医药（600056）子公司获布美他尼注射液批件
股市必读：中国医药（600056）7月23日董秘有最新回复
证券之星 · 07-24
股市必读：中国医药（600056）7月23日董秘有最新回复
中国医药（600056）披露子公司获得药品补充申请批准通知书，7月20日股价上涨1.59%
证券之星 · 07-20
中国医药（600056）披露子公司获得药品补充申请批准通知书，7月20日股价上涨1.59%
每周股票复盘：中国医药（600056）子公司获依折麦布原料药批文
证券之星 · 07-19
每周股票复盘：中国医药（600056）子公司获依折麦布原料药批文
中国医药(600056.SH)子公司化学原料药依折麦布上市申请获批
智通财经 · 07-16
中国医药(600056.SH)子公司化学原料药依折麦布上市申请获批
2025年度中国医药工业营收百强榜发布，齐鲁制药连续三年位列第三
蓝鲸财经 · 07-13
2025年度中国医药工业营收百强榜发布，齐鲁制药连续三年位列第三
加载更多
公司概况
公司名称：
中国医药健康产业股份有限公司
所属行业：
批发业
上市日期：
1997-05-15
主营业务：
中国医药健康产业股份有限公司的主营业务是医药领域的生产、加工和贸易。公司的主要产品是医药研发、医药工业、医药商业、医疗器械、国际贸易、中药大健康、电商业务。报告期内，公司入选药智网“2026化药研发实力TOP100”第72位。
发行价格：
7.02
{"stockData":{"symbol":"600056","market":"SH","secType":"STK","nameCN":"中国医药","latestPrice":9.26,"timestamp":1787881022000,"preClose":9.35,"halted":0,"volume":1010700,"delay":0,"changeRate":-0.0096,"floatShares":1495000000,"shares":1496000000,"eps":0.2864,"marketStatus":"交易中","change":-0.09,"latestTime":"08-28 09:37:02","open":9.3,"high":9.32,"low":9.25,"amount":9377200,"amplitude":0.0075,"askPrice":9.27,"askSize":207,"bidPrice":9.26,"bidSize":798,"shortable":0,"etf":0,"ttmEps":0.2864,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1787887800000},"marketStatusCode":2,"adr":0,"adjPreClose":9.35,"symbolType":"stock","openAndCloseTimeList":[[1787880600000,1787887800000],[1787893200000,1787900400000]],"highLimit":10.29,"lowLimit":8.42,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1495879748,"isCdr":false,"pbRate":1.17,"roa":"--","peRate":32.332402,"roe":"2.08%","epsLYR":0.3164,"committee":0.659613,"marketValue":13852000000,"turnoverRate":0.0007,"status":1,"floatMarketCap":13847000000},"requestUrl":"/m/hq/s/600056","defaultTab":"news","newsList":[{"id":"2662740312","title":"中国医药（600056）2026年中报简析：净利润同比下降15.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662740312","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662740312?lang=zh_cn&edition=full","pubTime":"2026-08-27 06:02","pubTimestamp":1787781737,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期中国医药发布2026年中报。根据财报显示，中国医药净利润同比下降15.26%。截至本报告期末，公司营业总收入169.52亿元，同比下降0.73%，归母净利润2.49亿元，同比下降15.26%。按单季度数据看，第二季度营业总收入87.63亿元，同比上升2.51%，第二季度归母净利润6691.42万元，同比下降44.88%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700010794.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056","03069"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662749516","title":"股市必读：中国医药中报 - 第二季度单季净利润同比下降44.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662749516","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662749516?lang=zh_cn&edition=full","pubTime":"2026-08-27 02:20","pubTimestamp":1787768423,"startTime":"0","endTime":"0","summary":"业绩披露要点：2026年第二季度单季度归母净利润6691.42万元，同比下降44.88%。业绩披露要点财务报告2026年中报显示，上半年度主营收入169.52亿元，同比下降0.73%；归母净利润2.49亿元，同比下降15.26%；扣非净利润2.31亿元，同比下降9.81%；第二季度单季度主营收入87.63亿元，同比上升2.51%；单季度归母净利润6691.42万元，同比下降44.88%；单季度扣非净利润5316.83万元，同比下降43.65%；负债率62.69%，投资收益1252.66万元，财务费用1.25亿元，毛利率10.86%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700006817.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056","03069"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662465759","title":"图解中国医药中报：第二季度单季净利润同比下降44.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662465759","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662465759?lang=zh_cn&edition=full","pubTime":"2026-08-26 01:40","pubTimestamp":1787679645,"startTime":"0","endTime":"0","summary":"证券之星消息，中国医药2026年中报显示，上半年度公司主营收入169.52亿元，同比下降0.73%；归母净利润2.49亿元，同比下降15.26%；扣非净利润2.31亿元，同比下降9.81%；其中2026年第二季度，公司单季度主营收入87.63亿元，同比上升2.51%；单季度归母净利润6691.42万元，同比下降44.88%；单季度扣非净利润5316.83万元，同比下降43.65%；负债率62.69%，投资收益1252.66万元，财务费用1.25亿元，毛利率10.86%。财报数据概要请见下图:本文数据来源于中国医药2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600004235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056","03069"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660491288","title":"股市必读：中国医药（600056）8月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2660491288","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660491288?lang=zh_cn&edition=full","pubTime":"2026-08-19 02:55","pubTimestamp":1787079311,"startTime":"0","endTime":"0","summary":"截至2026年8月18日收盘，中国医药报收于9.44元，下跌0.63%，换手率0.88%，成交量13.22万手，成交额1.25亿元。董秘最新回复投资者： 要推动科技创新成果在卫生健康领域转化运用，推进全民健康数智化建设。请问公司在科技创新和健康数智化建设做了什么工作董秘： 您好！公司将结合自身业务实际，稳步推动科技创新成果转化与数智化转型升级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900001998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0185","600056","BK0175","BK0250","BK0028","03069","BK0010","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660463135","title":"中国医药：构建“小通智慧云药房”","url":"https://stock-news.laohu8.com/highlight/detail?id=2660463135","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660463135?lang=zh_cn&edition=full","pubTime":"2026-08-18 16:57","pubTimestamp":1787043439,"startTime":"0","endTime":"0","summary":"证券之星消息，中国医药08月18日在投资者关系平台上答复投资者关心的问题。请问公司在科技创新和健康数智化建设做了什么工作中国医药回复：您好！公司构建“小通智慧云药房”，提供云找药、互联网医院、健康管理等线上服务，同时扎实推进“数智穿透监管”与“AI+提效”两大工程。公司将结合自身业务实际，稳步推动科技创新成果转化与数智化转型升级。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800029033.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0185","BK0188","600056","BK0028","BK0175","03069","BK0010","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660431040","title":"股市必读：中国医药（600056）8月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2660431040","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660431040?lang=zh_cn&edition=full","pubTime":"2026-08-18 02:21","pubTimestamp":1786990869,"startTime":"0","endTime":"0","summary":"截至2026年8月17日收盘，中国医药报收于9.5元，下跌0.31%，换手率1.45%，成交量21.72万手，成交额2.05亿元。董秘最新回复投资者： 通用技术中国医药2026医药融合创新研讨会，请问公司邀请人来研讨，面对提问会回答吗？当日关注点交易信息汇总：8月17日主力资金净流出41.19万元，游资资金净流出1250.57万元，散户资金净流入1291.76万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800002311.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0185","03069","BK0010","600056","BK0175","BK0028","BK0250","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659176884","title":"每周股票复盘：中国医药（600056）子公司获氨甲环酸片上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2659176884","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659176884?lang=zh_cn&edition=full","pubTime":"2026-08-16 02:33","pubTimestamp":1786818790,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，中国医药报收于9.53元，较上周的9.4元上涨1.38%。本周关注点来自公司公告汇总：子公司天方药业获批氨甲环酸片上市许可持有人变更。公司公告汇总中国医药全资子公司天方药业有限公司收到国家药监局核准签发的氨甲环酸片《药品补充申请批准通知书》，同意该药品上市许可持有人由浙江兄弟药业有限公司变更为天方药业有限公司。截至目前，国内已有包括天方药业在内的18家生产企业获得该药品批件。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000624.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0250","BK0082","BK0175","BK0010","BK0028","03069","600056","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658125299","title":"股市必读：中国医药新发布《关于子公司获得药品补充申请批准通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658125299","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658125299?lang=zh_cn&edition=full","pubTime":"2026-08-12 00:59","pubTimestamp":1786467548,"startTime":"0","endTime":"0","summary":"公司公告汇总关于子公司获得药品补充申请批准通知书的公告中国医药全资子公司天方药业有限公司收到国家药监局核准签发的氨甲环酸片《药品补充申请批准通知书》，同意该药品上市许可持有人由浙江兄弟药业有限公司变更为天方药业有限公司。截至目前，国内已有包括天方药业在内的18家生产企业获得该药品批件。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200001328.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","BK0010","BK0188","BK0028","BK0185","BK0175","600056","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658378309","title":"中国医药（600056）披露子公司获得药品补充申请批准通知书，8月10日股价上涨0.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658378309","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658378309?lang=zh_cn&edition=full","pubTime":"2026-08-10 22:35","pubTimestamp":1786372517,"startTime":"0","endTime":"0","summary":"截至2026年8月10日收盘，中国医药报收于9.47元，较前一交易日上涨0.74%，最新总市值为141.66亿元。近日，中国医药全资子公司天方药业有限公司收到国家药监局核准签发的氨甲环酸片《药品补充申请批准通知书》，同意该药品上市许可持有人由浙江兄弟药业有限公司变更为天方药业有限公司。截至目前，国内已有包括天方药业在内的18家生产企业获得该药品批件。2025年该药品在中国三大终端六大市场销售额约为27,128万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000034457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056","BK0250","BK0175","BK0082","BK0188","BK0028","BK0010","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657339565","title":"股市必读：中国医药新发布《关于子公司参加第十二批全国药品集中采购拟中选的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657339565","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657339565?lang=zh_cn&edition=full","pubTime":"2026-08-05 02:33","pubTimestamp":1785868390,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘，中国医药报收于9.48元，下跌0.94%，换手率0.91%，成交量13.57万手，成交额1.3亿元。公司公告汇总：中国医药下属四家子公司参与第十二批全国药品集采，盐酸倍他司汀片等8个产品拟中选，采购周期为3年。若最终中标并签订合同，将有利于扩大销售规模，提升市场占有率和品牌影响力。目前采购协议尚未签订，存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500002203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","BK0028","BK0082","BK0185","BK0188","BK0175","BK0010","600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656303280","title":"股市必读：中国医药新发布《关于子公司参加第十二批全国药品集中采购拟中选的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656303280","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656303280?lang=zh_cn&edition=full","pubTime":"2026-08-04 01:05","pubTimestamp":1785776714,"startTime":"0","endTime":"0","summary":"截至2026年8月3日收盘，中国医药报收于9.57元，上涨0.1%，换手率0.74%，成交量11.03万手，成交额1.06亿元。公司公告汇总：下属四家子公司参与第十二批全国药品集采，盐酸倍他司汀片等8个产品拟中选，采购周期为3年。若最终中标并签订合同，将有利于扩大销售规模，提升市场占有率和品牌影响力。目前采购协议尚未签订，存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400001057.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056","BK0250","BK0175","BK0082","BK0188","BK0028","BK0010","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656327760","title":"中国医药(600056.SH)：盐酸倍他司汀片等药品拟中选全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2656327760","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656327760?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:55","pubTimestamp":1785750942,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国医药 发布公告，2026年7月31日，公司下属子公司参加了第十二批全国药品集中采购的投标。根据国家组织药品联合采购办公室现场公布的拟中选结果，公司产品盐酸倍他司汀片、富马酸伏诺拉生片、维生素B6注射液、沙库巴曲缬沙坦钠片、注射用硫酸艾沙康唑、甲苯磺酸艾多沙班片、卡络磺钠注射液、盐酸伐昔洛韦片拟中选本次集中采购。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475321.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国医药(600056.SH)：盐酸倍他司汀片等药品拟中选全国药品集中采购","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","600056","BK0010","BK0028","BK0188","BK0185","BK0082","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656169943","title":"每周股票复盘：中国医药（600056）拟出租美康大厦获年租金1047.25万","url":"https://stock-news.laohu8.com/highlight/detail?id=2656169943","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656169943?lang=zh_cn&edition=full","pubTime":"2026-08-02 01:59","pubTimestamp":1785607149,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，中国医药报收于9.56元，较上周的9.2元上涨3.91%。本周关注点公司公告汇总：中国医药下属子公司拟出租美康大厦，年租金1,047.25万元。其中，下属全资子公司中国医保拟与关联方康养公司签署《补充协议》，将美康大厦租赁期限调整为2026年7月1日至2029年6月30日，年租金1,047.25万元，租赁期内租金总额不超过3,141.75万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200000444.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0250","BK0185","BK0188","BK0175","BK0082","BK0028","600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654488878","title":"中国医药（600056）披露向关联方出租美康大厦事项，7月28日股价下跌0.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654488878","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654488878?lang=zh_cn&edition=full","pubTime":"2026-07-28 22:19","pubTimestamp":1785248355,"startTime":"0","endTime":"0","summary":"截至2026年7月28日收盘，中国医药报收于9.35元，较前一交易日下跌0.43%，最新总市值为139.86亿元。近日，中国医药健康产业股份有限公司披露第十届董事会第5次会议决议公告。公告显示，公司下属全资子公司中国医保拟与关联方康养公司签署《补充协议》，将美康大厦租赁期限调整为2026年7月1日至2029年6月30日，年租金1,047.25万元，租赁期内租金总额不超过3,141.75万元。该事项构成关联交易，关联董事已回避表决。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800039801.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0028","BK0082","BK0175","BK0188","BK0010","600056","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654052292","title":"每周股票复盘：中国医药（600056）子公司获布美他尼注射液批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2654052292","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654052292?lang=zh_cn&edition=full","pubTime":"2026-07-26 01:52","pubTimestamp":1785001936,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，中国医药报收于9.2元，较上周的9.46元下跌2.75%。本周关注点公司公告汇总：子公司天方药业获批布美他尼注射液上市许可变更公司公告汇总中国医药全资子公司天方药业有限公司收到国家药监局核准签发的布美他尼注射液《药品补充申请批准通知书》，药品上市许可持有人变更为天方药业，批准文号不变，生产场地、处方、生产工艺及质量标准与原药品一致。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0185","BK0188","600056","BK0028","BK0175","BK0010","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653720812","title":"股市必读：中国医药（600056）7月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2653720812","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653720812?lang=zh_cn&edition=full","pubTime":"2026-07-24 02:14","pubTimestamp":1784830454,"startTime":"0","endTime":"0","summary":"截至2026年7月23日收盘，中国医药报收于9.44元，上涨0.11%，换手率1.11%，成交量16.57万手，成交额1.56亿元。董秘最新回复投资者： 1.请问公司投资者问答什么时候可以恢复正常?公司严格按照监管要求履行信息披露义务，上半年经营情况请以后续正式披露的半年报为准。交易信息汇总资金流向7月23日主力资金净流出152.65万元，占总成交额0.0%；游资资金净流出1092.85万元，占总成交额0.0%；散户资金净流入1245.5万元，占总成交额0.0%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400001535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0028","BK0175","BK0010","600056","BK0188","BK0082","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652211995","title":"中国医药（600056）披露子公司获得药品补充申请批准通知书，7月20日股价上涨1.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652211995","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652211995?lang=zh_cn&edition=full","pubTime":"2026-07-20 22:22","pubTimestamp":1784557346,"startTime":"0","endTime":"0","summary":"截至2026年7月20日收盘，中国医药报收于9.61元，较前一交易日上涨1.59%，最新总市值为143.75亿元。近日，中国医药全资子公司天方药业有限公司收到国家药监局核准签发的布美他尼注射液《药品补充申请批准通知书》，该药品上市许可持有人由深圳格莱恩生物医药科技有限公司变更为天方药业。截至公告日，项目累计投入约146.52万元。国内已有46家生产企业拥有该药品批件，2025年全国销售额约26,233万元，2026年第一季度约4,263万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000039637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0010","BK0185","BK0250","BK0028","BK0082","BK0188","600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652230817","title":"每周股票复盘：中国医药（600056）子公司获依折麦布原料药批文","url":"https://stock-news.laohu8.com/highlight/detail?id=2652230817","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652230817?lang=zh_cn&edition=full","pubTime":"2026-07-19 02:15","pubTimestamp":1784398511,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，中国医药报收于9.46元，较上周的9.09元上涨4.07%。本周，中国医药7月17日盘中最高价报9.84元。中国医药当前最新总市值141.51亿元，在医药商业板块市值排名6/32，在两市A股市值排名1267/5199。截至公告日，天方药业在该药品原料和制剂累计投入约1,473.19万元。目前国内依折麦布原料药有26个登记号，其中18个状态为“A”。本次获批有助于公司拓展产品领域，完善心血管领域原料药布局。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000615.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0185","BK0010","BK0250","600056","BK0082","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651029414","title":"中国医药(600056.SH)子公司化学原料药依折麦布上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2651029414","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651029414?lang=zh_cn&edition=full","pubTime":"2026-07-16 15:56","pubTimestamp":1784188585,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国医药(600056.SH)发布公告，近日，公司下属全资子公司天方药业有限公司收到国家药品监督管理局核准签发的依折麦布《化学原料药上市申请批准通知书》。该药品主要用于原发性高胆固醇血症、纯合子家族性高胆固醇血症(HoFH)、纯合子谷甾醇血症(或植物甾醇血症)。此次原料药的获批将进一步拓展公司的产品领域，完善心血管领域原料药产品布局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","BK0010","BK0185","BK0250","BK0028","IPOS","BK0082","BK0188","600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651019168","title":"2025年度中国医药工业营收百强榜发布，齐鲁制药连续三年位列第三","url":"https://stock-news.laohu8.com/highlight/detail?id=2651019168","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651019168?lang=zh_cn&edition=full","pubTime":"2026-07-13 15:42","pubTimestamp":1783928549,"startTime":"0","endTime":"0","summary":"7月11日至12日，由中国医药工业信息中心等单位主办的第43届全国医药工业信息年会 & 2026北京·昌平生命科学论坛在北京召开。大会发布了备受行业关注的“2025年度中国医药工业主营业务收入前100位企业”以及“2026年中国医药研发产品线示范工业企业”“2026年中国医药工业企业社会责任优秀案例”等系列榜单。齐鲁制药集团第十一次跻身中国医药工业主营业务收入前100位企业，连续三年位居第三位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1783928491744277655","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["01477","600056"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787881027640,"stockEarnings":[{"period":"1week","weight":-0.026},{"period":"1month","weight":0},{"period":"3month","weight":-0.0475},{"period":"6month","weight":-0.1153},{"period":"1year","weight":-0.127},{"period":"ytd","weight":-0.0871}],"compareEarnings":[{"period":"1week","weight":0.0135},{"period":"1month","weight":0.0376},{"period":"3month","weight":-0.0275},{"period":"6month","weight":-0.0496},{"period":"1year","weight":0.0411},{"period":"ytd","weight":-0.0031}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"中国医药健康产业股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"124580人(较上一季度减少3.43%)","perCapita":"12003股","listingDate":"1997-05-15","address":"北京市丰台区西营街1号院1区1号楼25-28层","registeredCapital":"149587万元","survey":" 中国医药健康产业股份有限公司的主营业务是医药领域的生产、加工和贸易。公司的主要产品是医药研发、医药工业、医药商业、医疗器械、国际贸易、中药大健康、电商业务。报告期内，公司入选药智网“2026化药研发实力TOP100”第72位。","listedPrice":7.02},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国医药(600056)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国医药(600056)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国医药,600056,中国医药股票,中国医药股票老虎,中国医药股票老虎国际,中国医药行情,中国医药股票行情,中国医药股价,中国医药股市,中国医药股票价格,中国医药股票交易,中国医药股票购买,中国医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国医药(600056)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国医药(600056)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}